Conjunctivitis, commonly known as pink eye, is an irritating condition marked by redness, itching, and discharge that can leave the eyes feeling gritty and uncomfortable. It is highly contagious in its infectious forms, meaning an outbreak can quickly disrupt family routines or school and work schedules. Beyond the discomfort, pink eye requires attention because the underlying cause must be identified to ensure proper treatment and prevent spread to others.

Treatment is essential for relieving immediate symptoms and, in some cases, curing the infection to prevent potential complications. The medication approach depends entirely on the cause: viral, bacterial, or allergic. Viral cases are the most common but typically resolve on their own, while bacterial and allergic cases require targeted drug therapy. Medication choices rely heavily on a medical assessment of the type of discharge, the presence of other symptoms, and any known allergies (Centers for Disease Control and Prevention, 2021).

Overview of treatment options for Conjunctivitis (Pink Eye)

The main goal of treating conjunctivitis is symptom management and eliminating the infectious agent when present. Supportive care such as using warm compresses for infectious discharge or cold compresses for allergic swelling is often the first step. Medications are then categorized based on the specific type of pink eye diagnosed.

For bacterial and severe allergic cases, medications are required to treat the cause. For the vast majority of viral cases, however, medications (specifically antibiotics) are ineffective and therefore avoided. This distinction is critical to prevent unnecessary drug use and potential resistance. Only severe or complicated forms, such as those caused by the Herpes simplex virus, may require antiviral medication, but this is rare in general practice.

Medications used for Conjunctivitis (Pink Eye)

When the cause is determined to be bacterial, doctors prescribe topical antibiotics, usually in the form of eye drops or ointments. Common examples include polymyxin B with trimethoprim, erythromycin, or fluoroquinolone drops (such as ciprofloxacin). These medications relieve symptoms by targeting the bacterial growth on the eye’s surface. Improvement in redness and discharge is often noticeable within 24 to 48 hours of starting the drops.

If the pink eye is caused by an allergic reaction to pollen, dust, or dander, the primary treatment involves antihistamines and mast cell stabilizers. These are available as drops (like olopatadine or azelastine) and often work quickly to stop the intense itching and redness. For severe inflammation, nonsteroidal anti-inflammatory drug (NSAID) drops, such as ketorolac, may be used to reduce swelling and irritation. Oral antihistamines can also be used to manage systemic allergic symptoms.

How these medications work

Antibiotic eye drops work by interfering with the bacteria’s vital life processes. They may prevent the bacteria from building their cell walls or stop them from producing the proteins necessary for reproduction. By inhibiting these functions, antibiotics halt the spread of the infection and allow the body’s immune system to clear the remaining pathogens.

Antihistamine drops work by blocking the action of histamine, a chemical the body releases during an allergic reaction. Histamine is responsible for the classic allergic symptoms, the intense itching, swelling, and increased blood flow that causes redness. By blocking the histamine receptors, these drugs prevent the allergic cascade from occurring. Mast cell stabilizers work by preventing the release of histamine in the first place, offering longer-term preventative relief for seasonal allergies (American Academy of Ophthalmology, 2022).

Side effects and safety considerations

Topical eye medications are generally safe, though temporary side effects like mild stinging, burning, or temporary blurred vision (especially with ointments) are common. Allergic patients might feel a slight sting from antihistamine drops.

Crucially, avoid antibiotic drops for viral infections, as they are ineffective and can lead to resistance. Steroid drops are for severe cases and require caution, as they can worsen viral infections. Seek immediate medical attention for sudden, severe eye pain, extreme light sensitivity, or vision loss, as these signal a serious issue (Mayo Clinic, 2023).

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American Academy of Ophthalmology. https://www.aao.org
  2. Centers for Disease Control and Prevention. https://www.cdc.gov
  3. Mayo Clinic. https://www.mayoclinic.org
  4. National Eye Institute. https://www.nei.nih.gov

Medications for Conjunctivitis (Pink Eye)

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Conjunctivitis (Pink Eye).

Found 22 Approved Drugs for Conjunctivitis (Pink Eye)

Azithromycin

Brand Names
Azasite, Zithromax

Azithromycin

Brand Names
Azasite, Zithromax
Azithromycin for oral suspension USP is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

CycloSPORINE

Brand Names
Restasis MultiDose, Neoral, VEVYE, CEQUA, Sandimmune, Restasis, Verkazia, Gengraf

CycloSPORINE

Brand Names
Restasis MultiDose, Neoral, VEVYE, CEQUA, Sandimmune, Restasis, Verkazia, Gengraf
Kidney, Liver, and Heart Transplantation Cyclosporine capsules (modified) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules (modified) has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Cyclosporine capsules (modified) is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with cyclosporine capsules (modified) as with other therapies upon cessation of treatment.

Ketorolac Tromethamine

Brand Names
Sprix, Toronova, Ketorocaine, Strenza, Toronova SUIK, Acuvail, Acular

Ketorolac Tromethamine

Brand Names
Sprix, Toronova, Ketorocaine, Strenza, Toronova SUIK, Acuvail, Acular
Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. ( 1 )

Tobramycin

Brand Names
TOBI Podhaler, TOBI, Bethkis, TobraDex, Tobrex

Tobramycin

Brand Names
TOBI Podhaler, TOBI, Bethkis, TobraDex, Tobrex
Tobramycin injection is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase- and non-penicillinase-producing strains) Serious central-nervous-system infections (meningitis) caused by susceptible organisms Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp Skin, bone, and skin structure infections caused by P. aeruginosa, Proteus sp, E. coli, Klebsiella sp, Enterobacter sp and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus sp, (indole-positive and indole- negative), E. coli, Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus, Providencia sp, and Citrobacte r sp. Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram- negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection and other antimicrobial drugs, Tobramycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Moxifloxacin

Brand Names
Strenza, Vigamox

Moxifloxacin

Brand Names
Strenza, Vigamox
Moxifloxacin is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia.
Showing 1-5 of 22
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances